GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™).
Source: GSK news - Category: Pharmaceuticals Source Type: news